BioSpace News Archive

Publication describes favorable safety profile and efficacy in neurologic and other disease features in individual NPC patients following intravenous administration of drug

Liberty Health Sciences Inc. www.libertyhealthsciences.com, a provider of high quality cannabis, announced its financial results for the second quarter ended August 31, 2019.

Eyenovia, Inc., a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, announced that the Company will release financial results for the third quarter ended September 30, 2019 on Wednesday, November 13, 2019, after the market closes.

CareDx, Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the quarter ended September 30, 2019.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it will report financial results for the third quarter 2019, Thursday, November 7th, after U.S. financial markets close.

Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced it will host an investor event to review the full safety, clinical efficacy, and biomarker data from Part 1 of the Phase 1/2 clinical trial of RP1 alone and in combination with Opdivo®

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics, provided a regulatory and clinical update on IDE196 following receipt of meeting minutes from an End‑of‑Phase 1 (EOP1) meeting with the FDA.

Medpace Holdings, Inc. announced that it will present at the following investor conference in November

Achieved target number of 22 clinical sites opened and recruiting patients in the U.S. and Belgium. Filed protocol amendment with the regulatory agencies in both countries to optimize the SARA-INT Phase 2b clinical trial

The amendment, which was filed with the FDA and AFMPS, proposes a reduction in the number of patients needed in SARA-INT based on fast deterioration of mobility seen in the SARA-OBS study in participants with sarcopenia